人羊膜来源成体干细胞的多向分化潜能

干细胞治疗被认为是一种非常有潜力的治疗手段,其中成体干细胞由于不存在伦理问题,更为广大学者所青睐。本研究成功从人羊膜间质细胞中分离纯化出具有自我更新能力和多向分化潜能的成体干细胞。首先从羊膜间质细胞中通过极限稀释法进一步分离得到羊膜来源成体干细胞(Amnion-derived stemcells,ADSC),分析其形态、生长方式及主要的免疫表型,并在体外分别将其向脂肪、成骨、内皮、肝细胞及神经细胞诱导分化。结果发现,ADSC在适宜条件下能够向3个胚层的细胞分化,经连续传代30次,其形态及表型稳定,并仍保持多向分化潜能。证实了ADSC的干细胞特性,可能为细胞治疗及干细胞工程提供种子细胞的新来源。     

成体干细胞可塑性的事实、质疑和展望

成体干细胞的可塑性是指存在于成年组织或器官中的不成熟细胞跨胚层分化的一种能力。近年来相关研究很多,有人认为成体干细胞具有可塑性,如造血干细胞可以分化为神经外胚层细胞和内胚层细胞：有人对其持怀疑态度,认为成年造血干细胞发育可塑性证据不足,成体干细胞不能跨胚层分化。由于分离纯化、检测手段等的局限,大多数研究均存在这样或那样的不足和误区,彻底研究清楚还有很长的路要走。     

胚胎干细胞向肝实质细胞体外定向诱导分化过程中的肝卵圆细胞

如果肝脏严重受损致使肝细胞大部分坏死,或由于某些原因 ( 肝毒性物质、致癌物质的作用 ) 抑制残存肝细胞增殖时,肝内前体／干细胞———肝卵圆细胞便被激活并分化生成肝细胞和胆管细胞等以参与肝修复 . 基于此理论,人们建立了啮齿类动物肝卵圆细胞诱导实验模型 . 但显然上述模型不适用于人类,所以有必要开发一种适用于人类的、高效的肝卵圆细胞的新诱导模型 . 选用小鼠胚胎干细胞,转成拟胚体分化 3 天后分组,诱导组添加肝细胞生长因子 (HGF) 、表皮生长因子 (EGF) 作定向诱导分化 . 其间用免疫细胞化学 (ICC) 检测肝卵圆细胞标志物 A6 等的表达,用流式细胞仪筛选肝卵圆细胞并行 RT-PCR 、透射电镜检测 . 所筛选的肝卵圆细胞进一步体外培养并进行 ICC 和 RT-PCR ,检测其分化生成成熟的肝细胞和胆管细胞的能力 . 研究证实胚胎干细胞体外定向诱导生成肝实质细胞的过程中,存在着有双向分化能力的肝卵圆细胞这个中间分化阶段 . 诱导组肝卵圆细胞分化率均显著地高于对照组,最高时可达 6.11% 左右 . HGF 和 EGF 能显著性诱导胚胎干细胞源性卵圆细胞的生成 . 流式细胞仪筛选 Sca-1+/CD34+ 细胞占总细胞数的 4.59% ,其中 A6 阳性肝卵圆细胞占 90.81% 左右 . 使用流式细胞仪可获得高富集的 A6+/Sca-1+/CD34+ 肝卵圆细胞 . 提供了一种可适用于人类的肝卵圆细胞的新诱导模型 .     

胚胎干细胞分化为肝细胞的研究进展

目前 ,细胞移植作为终末期肝病的辅助治疗方法 ,移植的细胞必须满足在受体肝脏中存活、增殖并可分化为成熟肝细胞两个重要条件 ,但目前应用的肝细胞来源有限 ,其功能随着培养时间的延长而逐渐下降等问题限制了这一治疗策略的广泛开展。作为具有发育全能性和无限增殖能力的细胞 ,胚胎干细胞向肝细胞的分化研究近年来引起了广泛的关注 ,并取得了较大的进展 ,寻找合适、高效的分化诱导方法是目前研究的热点之一。胚胎干细胞向肝细胞的分化研究既可以为临床细胞替代治疗提供合适的细胞来源 ,也可以在药物评估和肝脏发育分化基础研究方面起到重要的作用。通过概括肝脏和拟胚体分化发育的分子机制 ,对体外胚胎干细胞向肝细胞分化的几种诱导体系作了介绍 ,并对分化肝细胞的应用前景和存在的问题进行了讨论。     

骨髓间充质干细胞移植与肾脏病

骨髓间充质干细胞是目前广受关注的一群成体干细胞,具有取材容易,增殖能力强,生物学特性稳定,可以跨胚层分化,低免疫源性,参与受损组织修复等优点,随着组织工程的兴起和发展以及其自身所特有的生物学特性,人们逐渐认识到将骨髓间充质干细胞作为肾脏病移植治疗的种子细胞具有良好的应用前景。本文就骨髓间充质干细胞的生物学特性及其在肾脏病移植治疗中的进展做一综述。     

骨髓间充质干细胞移植与肾脏病

骨髓间充质干细胞是目前广受关注的一群成体干细胞,具有取材容易,增殖能力强,生物学特性稳定,可以跨胚层分化,低免疫源性,参与受损组织修复等优点,随着组织工程的兴起和发展以及其自身所特有的生物学特性,人们逐渐认识到将骨髓间充质干细胞作为肾脏病移植治疗的种子细胞具有良好的应用前景。本文就骨髓间充质干细胞的生物学特性及其在肾脏病移植治疗中的进展做一综述。     

骨髓间充质干细胞的多向分化潜能研究进展

骨髓间充质干细胞(bone marrow stromal stem cell,BMSSC)是成体干细胞中最受关注的细胞之一,它不仅在造血和免疫细胞发生发育中发挥重要作用,而且参与多种器官组织的再生和损伤修复,特别是近年来发现BMSSC具有向不同胚层来源细胞跨越分化(trans-differentiation)的可塑性,不仅有可能揭示细胞分化的新机制,而且为众多疾病的临床治疗提供了新思路。目前已揭示,BMSSC除了具有向成骨、软骨和脂肪细胞分化潜能外,还有向肝细胞、神经细胞、心肌细胞、血管内皮细胞和胰岛细胞等多向分化的潜能,本文就当前BMSSC的多向分化潜能研究进展作一综述。     

间充质干细胞诱导分化为胰岛β细胞的研究进展

间充质干细胞是一类具有多向分化潜能的成体干细胞,在体内外不仅可以被诱导分化为中胚层细胞,而且可以分化为内胚层和神经外胚层细胞。间充质干细胞易分离,体外可大量扩增,异体移植不引起免疫排斥反应,在细胞治疗和组织工程中具有广阔的应用前景。经过适当诱导,间充质干细胞可能成为胰岛β细胞的来源之一。就间充质干细胞的生物学性状和优势,以及诱导分化为胰岛β细胞的技术方法和发展趋势进行了综述。     

定向诱导小鼠ES细胞为肝脏细胞及其凝血因子Ⅷ, Ⅸ的表达

凝血因子Ⅷ, Ⅸ缺陷导致血友病A和B的发生, 肝细胞是产生凝血因子的器官, 利用肝细胞进行替代治疗是纠正凝血因子缺陷的根本办法, 但是其来源及利用存在难以克服的问题. ES细胞具有体外培养时保持未分化状态和无限的增殖能力, 具有在一定条件下可以分化发育成各个胚层细胞的潜能, 利用ES细胞源性肝细胞作为供体细胞, 解决了肝细胞来源困难、增殖能力差的难题. 体外分阶段定向诱导E14小鼠ES细胞分化为肝细胞, ICG摄取及PAS反应结果证实ES源性细胞具备肝细胞功能, 在此基础上, 利用RT-PCR法对诱导细胞初步进行了凝血因子Ⅷ, Ⅸ表达分析, 为进一步开展利用ES细胞纠正凝血因子缺乏奠定了研究基础.     

成体干细胞的可塑性:横向分化还是细胞融合?

近年来研究显示成体干细胞(adult stem cells)具有可塑性(plasticity),不仅可以生成它们所在组织的成熟细胞,而且在特定环境下能分化成其他组织类型细胞,这种跨系或跨胚层分化现象称为横向分化或转分化(transdifferentiation)。横向分化已为成体干细胞的研究和临床应用包括组织器官损伤的修复提供了新的思路和应用前景。然而,最近的一些研究进展又引出不同的解释,即成体干细胞的可塑性是由于细胞融合(cellfusion)的结果。在此,就成体干细胞的可塑性、横向分化、细胞融合等方面研究作一综述。     

Switching from bone marrow-derived neurons to epithelial cells through dedifferentiation and translineage redifferentiation

While the ability of stem cells to switch lineages has been suggested, the route(s) through which this may happen is unclear. To date, the best characterized adult stem cell population considered to possess transdifferentiation capacity is BM-MSCs (bone marrow mesenchymal stem cells). We investigated whether BM-MSCs that had terminally differentiated into the neural or epithelial lineage could be induced to transdifferentiate into the other phenotype in vitro. Our results reveal that neuronal phenotypic cells derived from adult rat bone marrow cells can be switched to epithelial phenotypic cells, or vice versa, by culture manipulation allowing the differentiated cells to go through, first, dedifferentiation and then redifferentiation to another phenotype. Direct transdifferentiation from differentiated neuronal or epithelial phenotype to the other differentiated phenotype cannot be observed even when appropriate culture conditions are provided. Thus, dedifferentiation appears to be a prerequisite for changing fate and differentiating into a different lineage from a differentiated cell population.     

精原干细胞的生命历程

精原干细胞是动物体内的一种成体干细胞,在睾丸微环境中可以像胚胎干细胞一样具有增殖、分化潜能。近年来借助于各种细胞学技术,人们对精原干细胞在不同睾丸微环境中的分化和发育状况进行了深入研究,睾丸内不同种类细胞间的相互作用以及特定微环境对干细胞转分化的影响,已成为本领域的热点核心内容。将从精原干细胞生命历程的角度讨论该过程中所取得的研究成果和存在的问题。     

New developments in stem cell biology and therapy. First meeting report from the working group of the German Society for Hematology and Oncology

The call for the meeting which took place in Heidelberg 13 January 2005, resulted in a high number of contributions covering a diversity of topics: embryonal stem cell research; molecular signaling pathways; assay systems for primitive, mesenchymal and epithelial stem cells; markers for transdifferentiation; and theoretical considerations including biomathematical modeling of stem cell development. The program was rounded off by pre-clinical and clinical applications of stem cell therapies, including new mobilization agents, treatment of myocardial infarction and chemoprotective gene transfer to stem cells.     

Issues in stem cell plasticity

Experimental biology and medicine work with stem cells more than twenty years. The method discovered for in vitro culture of human embryonal stem cells acquired at abortions or from?surplus” embryos left from in vitro fertilization, evoked immediately ideas on the posibility to aim development and differentiation of these cells at regeneration of damaged tissues. Recently, several surprising observations proved that even tissue‐specific (multipotent) stem cells are capable, under suitable conditions of producing a while spectrum of cell types, regardless, whether these tissues are derived from the same germ layer or not. This ability is frequently called stem cell plasticity but other authors also use different names ‐?non‐orthodox differentiation” or?transdifferentiation”. In this paper we wish to raise several important questions and problems related to this theme. Let us remind some of them: Is it possible to force cells of one‐type tissue to lool and act as cells of another tissue? Are these changes netural? Could these trans‐formations be used to treat diseases? What about the bioethic issue? However, the most serious task “still remains to be soloved ‐ how to detect, harvestand culture stem cells for therapy of certain diseases”.     

Transdifferentiation: why and how?

Cell therapy is based on the replacement of damaged cells in order to restore injured tissues. The first consideration is that an abundant source of cells is needed; second, these cells should be immunologically compatible with the guest and third, there should be no real threat of these cells undergoing malignant transformation in the future. Given these requirements, already differentiated adult cells or adult stem cells obtained from the body of the patient appear to be the ideal candidates to meet all of these demands. The utilization of somatic cells also avoids numerous ethical and political drawbacks and concerns. Transdifferentiation is the phenomenon by which an adult differentiated cell switches to another differentiated cell. This paper reviews the importance of transdifferentiation, discussing the cells that are suitable for this process and the methods currently employed to induce the change in cell type.     

Stem cell plasticity, cell fusion, and transdifferentiation

One of the most contentious issues in biology today concerns the existence of stem cell plasticity. The term "plasticity" refers to the capacity of tissue-derived stem cells to exhibit a phenotypic potential that extends beyond the differentiated cell phenotypes of their resident tissue. Although evidence of stem cell plasticity has been reported by multiple laboratories, other scientists have not found the data persuasive and have remained skeptical about these new findings. This review will provide an overview of the stem cell plasticity controversy. We will examine many of the major objections that have been made to challenge the stem cell plasticity data. This controversy will be placed in the context of the traditional view of stem cell potential and cell phenotypic diversification. What the implications of cell plasticity are, and how its existence may modulate our present understanding of stem cell biology, will be explored. In addition, we will examine a topic that is usually not included within a discussion of stem cell biology--the direct conversion of one differentiated cell type into another. We believe that these observations on the transdifferentiation of differentiated cells have direct bearing on the issue of stem cell plasticity, and may provide insights into how cell phenotypic diversification is realized in the adult and into the origin of cell phenotypes during evolution.     

Cardiomyocyte differentiation from embryonic and adult stem cells

In recent years multiple reports indicating that embryonic as well as adult stem cells can differentiate to cardiomyocytes have ignited discussions on whether these stem cells could lead to new therapies for patients with heart disease. Recent developments have been made in the generation of cardiomyocytes from both embryonic and adult stem cells, and progress towards clinical applications in patients with heart failure has been made. Nevertheless, controversies surrounding safety and transdifferentiation issues will need to be overcome before these stem cell approaches can reach their full potential.     

Potential of embryonic and adult stem cells in vitro

Recent developments in the field of stem cell research indicate their enormous potential as a source of tissue for regenerative therapies. The success of such applications will depend on the precise properties and potentials of stem cells isolated either from embryonic, fetal or adult tissues. Embryonic stem cells established from the inner cell mass of early mouse embryos are characterized by nearly unlimited proliferation, and the capacity to differentiate into derivatives of essentially all lineages. The recent isolation and culture of human embryonic stem cell lines presents new opportunities for reconstructive medicine. However, important problems remain; first, the derivation of human embryonic stem cells from in vitro fertilized blastocysts creates ethical problems, and second, the current techniques for the directed differentiation into somatic cell populations yield impure products with tumorigenic potential. Recent studies have also suggested an unexpectedly wide developmental potential of adult tissue-specific stem cells. Here too, many questions remain concerning the nature and status of adult stem cells both in vivo and in vitro and their proliferation and differentiation/transdifferentiation capacity. This review focuses on those issues of embryonic and adult stem cell biology most relevant to their in vitro propagation and differentiation. Questions and problems related to the use of human embryonic and adult stem cells in tissue regeneration and transplantation are discussed.